Recruiting
PHASE1
INTERVENTIONAL
NCT06982859
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.
Interventions
Name:
Retatrutide
Type:
DRUG
Description:
Administered SC
Name:
Semaglutide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo
TimeFrame:
Baseline, Week 28
Description:
Change from baseline in total cDI for comparison of retatrutide with placebo
Trial Information
NCT ID
NCT06982859
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025